This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be conducted in Texas, US.

This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC).

This study investigated the effectiveness of the combined treatment FOLFIRI with aflibercept (Zaltrap) outside of clinical trials in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment might be a safe second line option in patients who progressed after first-line treatment.

This phase 2 trial will investigate the safety and effectiveness of tisotumab vedotin (TTV) for the treatment of solid tumors. The main outcome will be the response rate to treatment. This trial will take place in the United States, France, and Italy.

This study investigated the effectiveness and safety of consolidation chemotherapy after initial treatment in locally advanced rectal cancer. Researchers suggested that this treatment is safe and is associated with improved cancer outcomes. 

This trial is examining the effectiveness of mFOLFOX6 (oxaliplatin, leucovorin, fluorouracil) and nivolumab (Opdivo) with and without a new cancer vaccine (CV301) for patients with colorectal cancer that has spread to the liver. The main outcome will be overall survival.

This trial is being conducted in California and New Jersey, US.

This study investigated the effectiveness of stereotactic body radiotherapy (SBRT) in metastatic (spread to other parts of the body) colorectal cancer outcomes. Researchers suggested that SBRT improves survival in these patients.

This trial is examining the effectiveness and safety of vicriviroc (VIC) plus pembrolizumab (Keytruda) in the treatment of advanced colorectal cancer. The main outcome to be measured is the tumor response to treatment. This trial is being conducted in the US and Canada.  

This study investigated long term rectal cancer outcomes in patients who received chemotherapy, radiation therapy, and transanal microsurgery. Researchers suggested that this treatment improves treatment outcomes and quality of life of patients.

This study investigated the complications after colorectal cancer (CRC) surgery in elderly patients. Researchers suggested that if the patient is fit enough to undergo surgery, it improves the cancer outcomes.